Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Los Altos Pharma In-licenses China Rights to Sedor's Pain Candidate

publication date: Jun 22, 2018

California's Los Altos Pharma has in-licensed greater China rights to a pain product in development from Sedor Pharma of Pennsylvania. Los Altos will have development, manufacturing and commercialization rights to Captisol-enabled™ (CE) Meloxicam. Sedor acquired rights to CE Meloxicam from Ligand Pharma, which applied its Captisol program to increase safety and bioavailability of the drug. Los Altos and Sedor will work to develop IM/IV CE-Meloxicam to treat acute post-surgery, trauma and cancer pain. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital